EOE-13 in the detection of hepatosplenic lymphoma.
Thirty-nine patients with lymphoma were evaluated prospectively to determine the usefulness of Ethiodol-Oil-Emulsion-13 (EOE-13) in the detection of hepatosplenic lymphoma by computed tomography. The detection rate in the spleen increased from 8% (before EOE-13 infusion) to 92% (after EOE-13 infusion). In ten of 39 patients (25%) in this series, lymphomatous disease was recognized only on the postinfusion computed tomographic scan. The postinfusion EOE-13 study demonstrated additional visceral abnormalities in 38% of the patients. The potential usefulness, limitations, and toxicity of this hepatosplenic-specific imaging agent are discussed.
D004998:Ethiodized Oil; D006689:Hodgkin Disease / Q000000981:diagnostic imaging*; D006801:Humans; D008113:Liver Neoplasms / Q000000981:diagnostic imaging*; D008223:Lymphoma / Q000000981:diagnostic imaging*; D011446:Prospective Studies; D013160:Splenic Neoplasms / Q000000981:diagnostic imaging*; D014057:Tomography, X-Ray Computed
C039040:ethiodized oil emulsion 13; D004998:Ethiodized Oil